Printer Friendly

Novel prion protein in BSE-affected Cattle, Switzerland.

To the Editor: In a recent issue of Emerging Infectious Diseases, Seuberlich et al. (1) reported a novel prion protein in cattle with bovine spongiform encephalopathy (BSE). Two cows in Switzerland, 8 and 15 years of age, tested positive in 2 approved screening tests, the PrioSTRIP test and the Prionics Check WESTERN (Prionics, Zurich, Switzerland). According to World Organisation for Animal Health guidelines, the 2 cattle are considered BSE positive. Histopathologic and immunohistochemical results were inconclusive because the tissues were severely autolyzed. Clinical signs were absent or the clinical history was not known.

After further analysis of brain tissues by using several monoclonal antibodies in a Western blot (WB), the authors concluded that they had identified an N-terminal truncated protease-resistant prion protein ([PrP.sup.res]) fragment that differs from the [PrP.sup.res] fragments in 3 known types of BSE. No reference was made to the existence of N-truncated fragments, such as C1, of the normal prion protein [PrP.sup.C], which have been reported for humans (2,3), mice (4), and cattle and other ruminants (5). The pattern in the WB of the novel prion protein (1) appears similar to that of the fragment C1 of the normal prion protein (2-5). The C1 fragment is more protease resistant than the intact [PrP.sup.C] fragment because the protein part is more protected by the polysaccharide residues. Could it be that in the case of the severely autolyzed tissues of the cows in Switzerland, the proteinase K might already have been weakened or inhibited and when combined with the higher protease resistance of the C1 fragment, the digestion was incomplete?

Ten years ago, I looked at nonspecific, unusual samples from fallen stock cattle in New Zealand. Samples from these cattle had been confirmed as negative by paraffin-embedded tissue blot (University of Gottingen, Gottingen Germany), sodium phosphotungstic acid precipitation, followed by WB (European Union Reference Laboratory for Transmissible Spongiform Encephalopathies, Veterinary Laboratories Agency, New Haw, UK), Prionics WB (Prionics AG, Zurich, Switzerland), histopathologic examination, and immunohistochemical testing (Veterinary Laboratories Agency). We became aware of such samples when the proteinase K digestion did not work properly (Figure). Unusual samples 1 and 2 contained increased amounts of a truncated fragment of normal [PrP.sup.C], which was digested completely after the proteinase K concentration was increased.

I am convinced that the novel [PrP.sup.res] described in the article by Seuberlich et al. (1) is indeed a truncated fragment of the normal bovine [PrP.sup.C] protein. Therefore, I would like to ask the editor to address the following issues with the authors: Why were no references to truncated fragments of [PrP.sup.C] made in their article? Why was no WB analysis performed in which the novel [PrP.sup.res] was shown next to normal, undigested [PrP.sup.C] for band-size comparison? Why were no WB analyses shown in which the proteinase K concentration was increased?

It is laudable that in vivo transmission studies using transgenic mouse models and cattle are under way, which will sort out these findings conclusively. I expect that no disease development will be shown. Meanwhile, announcing new types of BSE is purely speculation.

Reinhold Kittelberger

Author affiliation: Biosecurity New Zealand, Upper Hutt, New Zealand

DOI: http://dx.doi.org/10.3201/eid1805.111824

References

(1.) Seuberlich T, Gsponer M, Drogemuller C, Polak MP, McCutcheon S, Heim D, et al. Novel prion protein in BSE-affected cattle, Switzerland. Emerg Infect Dis. 2012;18:158-9. http://dx.doi.org/10.3201/ eid1801.111225

(2.) Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem. 1995;270:19173-80. http://dx.doi. org/10.1074/jbc.270.32.19173

(3.) Pan T, Li R, Wong B-S, Liu T, Gambetti P, Sy M-S. Heterogeneity of normal prion protein in two-dimensional immunoblot: presence of various glycosylated and truncated forms. J Neurochem. 2002;81:1092101. http://dx.doi.org/10.1046/j.1471-4159. 2002.00909.x

(4.) Mange A, Beranger F, Peoc'h K, Onoder T, Frobert Y, Lehmann S. Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. Biol Cell. 2004;96:125-32. http://dx.doi. org/10.1016/j.biolcel.2003.11.007

(5.) Klingeborn M. The prion protein in normal cells and disease. Studies on the cellular processing of bovine [PrP.sup.C] and molecular characterization of the Nor98 prion [dissertation]. Uppsala (Sweden): Swedish University of Agricultural Sciences; 2006.

Address for correspondence: Reinhold Kittelberger, Animal Health Laboratory, Investigation and Diagnostic Centre & Response, Biosecurity New Zealand, 66 Ward St, Upper Hutt 5018, New Zealand; email: reinhold.kittelberger@maf.govt.nz

In Response: Dr Kittelberger comments on our recent report of 2 cows in Switzerland that were classified as positive for bovine spongiform encephalopathy (BSE), according to the established criteria (1,2). He raises concerns that the unusual prion protein signature in Western blot (WB) in these cows represents a physiologic prion protein ([PrP.sup.C]) fragment, inefficiently degraded by proteinase K (PK), termed C1. Certainly the effects of tissue autolysis on PK activity and the molecular prion protein signature are of particular concern and deserve full consideration in data interpretation. In our study, molecular mass comparisons between [PrP.sup.C] in non-PK-treated brain tissue of healthy cattle and the prion protein in samples from the 2 aberrant cows with BSE in WB were considerably hindered by overlapping C1- and full-length [PrP.sup.C] bands in the non-PK-treated samples and did not allow for a robust conclusion (T. Seuberlich, unpub. data). It is noteworthy that the Prionics Check WESTERN (Prionics, Zurich, Switzerland) test has been extensively validated in terms of the diagnostic specificity, also on severely autolytic specimens (3-5). In none of these studies was a similar prion protein signature observed. We therefore considered it unlikely that the findings in the cases from Switzerland resulted from tissue autolysis.

Dr Kittelberger provides data from New Zealand cattle that revealed a similar prion protein signature in WB. He assumes that these animals had a negative BSE status and that the PK digestion in the WB did not work properly, which is supported by results from other diagnostic techniques. However, information about the degree of autolysis of these samples is missing, and, most notably, whether these findings are correlated with prion infectivity is not known. Strikingly, in contrast to the results for the samples from Switzerland, the samples from New Zealand are reported to be negative in the Prionics Check WESTERN. It would be fascinating to perform a side-by-side analysis of the samples from Switzerland and from New Zealand to determine whether the banding characteristics in both groups are identical. Studies are under way in our laboratory to further investigate the effect of tissue autolysis on PK activity and [PrP.sup.C] degradation under experimental conditions. If our findings turn out to be the result of inhibited PK activity in BSE-negative cattle samples, the current diagnostic criteria might require revision. As long as the results of these experiments and the ongoing transmission studies are not available, we can neither confirm nor reject a novel type of BSE.

Torsten Seuberlich

Author affiliation: University of Berne, Berne, Switzerland

DOI: http://dx.doi.org/10.3201/eid1805.120226

References

(1.) Seuberlich T, Gsponer M, Drogemuller C, Polak MP, McCutcheon S, Heim D, et al. Novel prion protein in BSE-affected cattle, Switzerland. Emerg Infect Dis. 2012;18:158-9. http://dx.doi.org/10.3201/ eid1801.111225

(2.) Kittelberger R. Novel prion protein in BSE-affected cattle, Switzerland [letter]. Emerg Infect Dis 2012;18:890-2. http:// dx.doi.org/10.3201/eid1805.111824

(3.) Schaller O, Fatzer R, Stack M, Clark J, Cooley W, Biffiger K, et al. Validation of a western immunoblotting procedure for bovine PrP(Sc) detection and its use as a rapid surveillance method for the diagnosis of bovine spongiform encephalopathy (BSE). Acta Neuro pathol. 1999;98:437-43. http://dx.doi. org/10.1007/s004010051106

(4.) European Food Safety Authority. Scientific report on the evaluation of seven new rapid post mortem BSE tests. EFSA Scientific Report. 2004;18:1-13 [cited 2012 Mar 1]. http://www.efsa.europa.eu/en/scdocs/doc/18r.pdf

(5.) Office International des Epizooties. OIE procedure for validation and certification of diagnostic assays. Abstract sheet for the Prionics-AG Check WESTERN [cited 2012 Mar 1]. http://www.oie.int/ fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/Abstract_20sheet_ OIE_20Register_PrionicsWB_v1.pdf

Address for correspondence: Torsten Seuberlich, NeuroCentre, National and OIE Reference Laboratories for BSE and Scrapie, University of Berne, Bremgartenstrasse 109a, CH- 3001 Berne, Switzerland; email: torsten. seuberlich@vetsuisse.unibe.ch
COPYRIGHT 2012 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTERS; bovine spongiform encephalopathy
Author:Kittelberger, Reinhold
Publication:Emerging Infectious Diseases
Article Type:Letter to the editor
Geographic Code:8NEWZ
Date:May 1, 2012
Words:1438
Previous Article:High anti-phenolic glycolipid-I IgM titers and hidden leprosy cases, Amazon Region.
Next Article:Health and the Myrmidons.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters